Roches Genentech targets cancer cells via video game with Tumor Quest

fiercepharma | June 21, 2019

Roches Genentech targets cancer cells via video game with Tumor Quest
Roches Genentechs latest innovation targets cancer cells in a video game. Called Tumor Quest, the game is aimed at engaging people in an out of the-ordinary way to talk about tumor types and biomarker testing. The game begins with a short intro video about genomic profiling and testing, with players then able to choose from three different paths—non-specific, tumor-specific or tumor-agnostic—to try to eliminate cancer cells. Tumor Quest uses “Bejeweled” type matching play, where players line up three or more mutations associated with different tumor types that then disappear. For instance, in tumor-agnostic, a player earns points for matching a colon, lung and pancreas based on the same mutation. Genentech launched the game on its website gene.com around ASCO earlier this month knowing that many of its priority audiences would be attending. Genentech promoted it on Twitter (@genentech), shared it on Facebook and LinkedIn and sent it to key influencers in the community. “While (personalized medicine) is obviously an extremely complex topic, we’ve peeled it back to its most basic concepts to hopefully make it easy to understand how we can tailor treatments based on the unique biology of an individual’s cancer. And we’ve used a gaming platform that will feel familiar and intuitive to most players,” Josh Baldwin, Genentech's director of digital strategy and channels, corporate relations, said in an email interview. For Genentech, the video game is the latest in trying to engage people with content that goes beyond traditional editorial and video, which have already included animations, comic strips, podcasts and other video games.

Spotlight

NO OTHER NATURAL OR SYNTHETIC POLYMER PROVIDES GELATINE’S UNIQUE TECHNOLOGICAL AND BIOPHARMACEUTICAL ADVANTAGES.

Related News

PHARMA TECH

Iktos Announces Deployment of their AI for Drug Design Software Makya™ by Chiesi Group

Iktos and Chiesi Group | December 03, 2021

ktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Makya™ will be used by Chiesi scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Chiesi’s drug discovery programmes. Iktos has released Makya™, a generative AI-driven de novo design software for Multi-Parametric Optimization available either as a SaaS platform or for implementation on customer premises or in the customer’s Virtual Private Cloud. Makya’s user-friendly interface enables it to be used by medicinal or computational chemists. Makya™ can also be operated as a Python package through a Jupyter notebook interface. Iktos’ AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process, by automatically designing virtual novel molecules that have desired activities for treating a given disease. This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for drug discovery and development. “Licensing Makya is another step Chiesi wanted to complete in digitalization of R&D and in particular in drug discovery. The possibility of applying cutting edge AI technology relying on our internal expertise and historical data to drug design is very appealing. We think this emerging technology will become soon part of the compound design toolkit for all medicinal chemists, to facilitate their work aimed at identifying the right molecule”. Maurizio Civelli, Head of Global Research and Pre-Clinical Development Area of Chiesi Group “We are proud to work with Chiesi Farmaceutici, one of the top 50 pharmaceutical companies in the world, and to have their scientists use our software in their early discovery programs”, said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “It is our ultimate goal to put our technology in the hands of drug discovery scientists, who have deep knowledge and understanding of their discovery programs. By combining their drug discovery expertise with our algorithmic and data science know-how and experience derived from the many collaborations we have established to date, we believe that the promise of AI to dramatically improve drug discovery will have a better chance to be realized and impact therapeutic development”. About Iktos Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. About Chiesi Group Based in Parma, Italy, Chiesi is an international research-focused pharmaceutical and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE and CARE. The Group’s Research and Development centre is based in Parma and works alongside six other important research and development hubs in France, the U.S., Canada, China, the UK and Sweden to pursue its pre-clinical, clinical and regulatory programmes. In 2018 Chiesi changed its legal status to Benefit Corporation, according to the law in Italy, the USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders committed to using business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has incorporated. The Group is committed to becoming carbon neutral by the end of 2035.

Read More

PHARMA TECH

FDA Grants Breakthrough Device Designation to JelikaLite

JelikaLite Corp | January 07, 2022

JelikaLite Corp, a medical technology company, announced that the U.S. Food and Drug Administration has granted the Breakthrough Device Designation to its Cognilum System for the reduction of symptoms of moderate to severe autism spectrum disorder in pediatric patients who are 2 to 6 years of age. The FDA’s Breakthrough Device Program recognizes medical devices that meet the criteria and hold the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or condition. Data from a pilot study suggests that Cognilum, a wearable medical device, can significantly improve the symptoms of children living with autism. If approved, it will offer families access to a home-based, easy-to-use, and cost-effective treatment for children with autism not available anywhere else. Autism is a serious developmental disorder that impacts families around the globe. JelikaLite Corp. believes that it can provide relief to patients and families by reducing children's autism symptoms. Children will be able to better integrate into the society and have more fulfilling lives. Their caregivers can lead less stressful lives and both insurance companies and the government will be able to spend less money on effective intervention, special education and lifelong residential care. The Breakthrough Device Designation for Cognilum was based on the results of a double-blind, placebo controlled clinical trial of 30 pediatric patients with moderate to severe autism. The trial showed both safety and efficacy of this technology. By combining non-invasive brain stimulation with near-infrared light, EEG sensors, and AI personalization platform, Cognilum demonstrated improvements in autism symptoms through gains in communication and daily living skills. "We are thrilled that the FDA recognizes that we are developing a novel technology with a potential to change the landscape in the current approach to Autism. For some of the participants in our active condition, the positive change was so dramatic that their parents expressed their desire to continue the treatment even after the study was over. We recognize that Autism is a spectrum, and no two children are alike; our ultimate goal is to develop a personalized approach to every child based on their unique needs and challenges.” Dr. Eugenia Steingold, Chief Science Officer of JelikaLite JelikaLite’s vision is to bring Cognilum into the homes of families raising children with autism around the globe. This device is truly unique as it seeks to offer a personalized treatment for each child with an integrated feedback loop for both caregivers and doctors. About JelikaLite Based in New York, JelikaLite was launched in 2019 to develop Cognilum™, an innovative solution to permanently reduce children's autism symptoms, enabling better integration into society and reducing lifelong costs. Cognilum™ is a data-device integrated system, where a wearable non-invasive therapeutic medical device that provides neurostimulation treatment is combined with an AI personalization platform. JelikaLite has been founded and run by a multidisciplinary team, with experts in autism clinical therapy, transcranial photobiomodulation, commercialization of medical devices, artificial intelligence, product management, and finance.

Read More

Allied Expands Pharmaceutical Pipeline By Filing US Provisional Patent for Psilocybin Based Therapeutics

Allied Corp | October 21, 2020

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety. Psilocybin is the active pharmaceutical ingredient contained in the Golden Teacher psychedelic mushroom. Along with the novel treatment regimen, Allied’s formulation consists of novel micro-dose ratios of several medical mushroom compounds combined with additional natural health molecules.

Read More

Spotlight

NO OTHER NATURAL OR SYNTHETIC POLYMER PROVIDES GELATINE’S UNIQUE TECHNOLOGICAL AND BIOPHARMACEUTICAL ADVANTAGES.